Clinical Trials & Good Clinical Practices (GCP) Training
Good Clinical Practices (GCP) ensure patient safety and product efficacy. Because of this, global health authorities require GCP training for companies in the life sciences, biotech, and medical device industries.
Life Science Training Institute creates live and on-demand training solutions for individuals and organizations working with GCP.
Our trainers are industry subject matter experts (SMEs) who average over 20 years of life science and pharmaceutical experience.
Browse our clinical and GCP training courses below.
-
$279
-
$179
It is Finally Here! Update to the ISO Medical Device GCP Standard: ISO 14155:2020Sandra “SAM” SatherOn-Demand -
$179
Preparing for Changes to ICH GCP E6(R3) and ICH E8(R1) – Readying for Risk MitigationSandra “SAM” SatherOn-Demand -
$279
Quality Management of Electronic Systems in Clinical Trial Investigations: A Comparison of FDA and EMA GuidanceSandra “SAM” SatherOn-Demand -
$279
Regulatory Affairs in China – The New Drug Regulatory FrameworkMichael Zhang, Katrin RupallaOn-Demand
-
$179
-
$179
Critical Documentation of Clinical Trial Activities and CAPA During and Post COVID-19 RestrictionsSandra “SAM” SatherOn-Demand -
$179
Conducting a Virtual GCP Audit of a CRO Managed Study During the COVID-19 PandemicMichael PierroOn-Demand -
$179
Remote Auditing for GMP Compliance During COVID-19: Challenges and OpportunitiesMark Allen DurivageOn-Demand -
$179
Remote Monitoring Operations While Maintaining HIPAA and GCP During COVID-19 RestrictionsSandra “SAM” SatherOn-Demand -
$279
FDA REMS Inspection Guide: Audit Preparedness Best PracticesPenelope Przekop, MSQA, RQAP-GCPOn-Demand -
$279
Clinical Research Project Management – 7 Breakthrough Behaviors For SuccessDalfoni BanerjeeOn-Demand -
$279
Identifying Workforce Gaps Post Risk-Based Monitoring (RBM): It’s Time to “DIG” in!Sandra “SAM” SatherOn-Demand -
$279
Applying Six Sigma Tools and Concepts in Clinical Research: A Process Improvement GuideBetsy FallenOn-Demand -
$279
-
$279
New FDA Draft Guidance: A Risk-Based Approach to Monitoring Clinical InvestigationsSandra “SAM” SatherOn-Demand